|
Treatment groupa
|
|---|
|
Characteristic
|
QIV
|
LD QIV-AS
|
LD TIV-AS
|
TIV
|
Total
|
|
Nb
|
104
|
104
|
104
|
105
|
417
|
|
Age (years)
|
|
Mean ± SD
|
38.6 ± 11.82
|
37.7 ± 12.30
|
36.7 ± 12.84
|
37.4 ± 12.51
|
37.6 ± 12.35
|
|
Median
|
38.0
|
37.0
|
33.5
|
36.0
|
36.0
|
|
Range (min–max)
|
19–59
|
18–59
|
18–59
|
18–59
|
18–59
|
|
Gender n(%)
|
|
Female
|
60 (57.7)
|
66 (63.5)
|
66 (63.5)
|
58 (55.2)
|
250 (60.0)
|
|
Male
|
44 (42.3)
|
38 (36.5)
|
38 (36.5)
|
47 (44.8)
|
167 (40.0)
|
|
Race n(%)
|
|
African heritage
|
1 (1.0)
|
0
|
0
|
0
|
1 (0.2)
|
|
White Caucasian
|
103 (99.0)
|
104 (100)
|
104 (100)
|
105 (100)
|
416 (99.8)
|
-
a Groups were administered the quadrivalent influenza vaccine (QIV), the low-dose adjuvanted quadrivalent influenza vaccine (LD QIV-AS), the low-dose adjuvanted trivalent influenza vaccine (LD TIV-AS) or the trivalent influenza vaccine (TIV).
-
b Abbreviations: N = total number of participants, n(%) = number (percentage) of participants with characteristic, min–max = minimum to maximum, SD = standard deviation.
